Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension...

por Damy, Thibaud, Sultan, Marla B., Witteles, Ronald
Publicado 2021

A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus

por Dombi, Theresa, Kwok, Kenneth K, Sultan, Marla B
Publicado 2012

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

por Sultan, Marla B, Gundapaneni, Balarama, Schumacher, Jennifer, Schwartz, Jeffrey H
Publicado 2017

Practice patterns of ophthalmologists administering intravitreal injections in Europe: a longitudinal survey

por Huang, Kui, Sultan, Marla B, Zhou, Duo, Tressler, Charles S, Mo, Jingping
Publicado 2016

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis O...

por Mundayat, Rajiv, Stewart, Michelle, Alvir, Jose, Short, Sarah, Ong, Moh-Lim, Keohane, Denis, Rill, Denise, Sultan, Marla B.
Publicado 2018

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

por Nativi‐Nicolau, Jose, Judge, Daniel P., Hoffman, James E., Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B., Grogan, Martha
Publicado 2021

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers

por Lockwood, Peter A., Le, Vu H., O'Gorman, Melissa T., Patterson, Terrell A., Sultan, Marla B., Tankisheva, Ekaterina, Wang, Qiang, Riley, Steve
Publicado 2020

Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story

por Burton, Arianna, Castaño, Adam, Bruno, Marianna, Riley, Steve, Schumacher, Jennifer, Sultan, Marla B, See Tai, Sandi, Judge, Daniel P, Patel, Jignesh K, Kelly, Jeffery W
Publicado 2021

Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial

por Shah, Sanjiv J., Fine, Nowell, Garcia-Pavia, Pablo, Klein, Allan L., Fernandes, Fabio, Weissman, Neil J., Maurer, Mathew S., Boman, Kurt, Gundapaneni, Balarama, Sultan, Marla B., Elliott, Perry
Publicado 2023

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

por Damy, Thibaud, Garcia‐Pavia, Pablo, Hanna, Mazen, Judge, Daniel P., Merlini, Giampaolo, Gundapaneni, Balarama, Patterson, Terrell A., Riley, Steven, Schwartz, Jeffrey H., Sultan, Marla B., Witteles, Ronald
Publicado 2020

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

por Elliott, Perry, Drachman, Brian M., Gottlieb, Stephen S., Hoffman, James E., Hummel, Scott L., Lenihan, Daniel J., Ebede, Ben, Gundapaneni, Balarama, Li, Benjamin, Sultan, Marla B., Shah, Sanjiv J.
Publicado 2021